Enterprise Value
175.6M
Cash
83.04M
Avg Qtr Burn
-7.714M
Short % of Float
6.27%
Insider Ownership
2.49%
Institutional Own.
61.39%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADX-2191 (methotrexate injection (DHFR inhibitor)) Details Eye disease , Proliferative vitreoretinopathy, Primary Vitreoretinal Lymphoma, Rare diseases, Retinitis Pigmentosa | NDA FDA meeting | |
Reproxalap Details Dry eye syndrome | Phase 3 Data readout | |
Reproxalap (ADX-102) Details Rare genetic disease, Rare diseases, Allergic conjunctivitis | Phase 3 Update | |
ADX-629 Details Sjögren-Larsson Syndrome | Phase 2 Data readout | |
ADX-629 Details Alcoholic hepatitis, Liver disease | Phase 2 Data readout | |
ADX-629 Details Chronic cough | Phase 2 Update | |
ADX-629 Details Idiopathic Nephrotic Syndrome | Phase 2a Data readout | |
ADX-629 Details Atopic dermatitis | Phase 2a Update | |
ADX-246 Details Atopic dermatitis, Skin disease/disorder | Phase 1/2 Data readout | |
ADX-248 Details Age-related macular degeneration, Geographic atrophy | Phase 1/2 Initiation |